Fundraising Fox
🦊/Companies
Sign in

Inventprise

Redmond, US · Founded 2012 · Washington LLC · 91 employees on LinkedIn

Find your way into Inventprise

358 people in our graph share verified history with the Inventprise team — schools, employers, funds. One of them is your warm intro.

Stephane Kurganunlockedknows Yves Leurquin · together at Université libre de Bruxelles (overlapped)
knows the team · via GlaxoSmithKline Biologicals
×3knows the team · via Cardinal Health
knows the team · via Symbiosis Institute of Management Studies
×4knows the team · via Savitribai Phule Pune University
knows the team · via Catalent

Inventprise is a clinical-stage vaccine developer using its proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker conjugation platform to create conjugate vaccines, including a lead pediatric pneumococcal conjugate vaccine (IVT PCV-25) and candidates for Group B Streptococcus and mRNA-based vaccines. The company also operates automated manufacturing facilities intended to supply global vaccine demand.

BiotechHealthtech

Founders & leadership

Inventprise was founded in 2012 by Subhash Kapre.

SKSubhash Kapre
Subhash KapreinFounder · Executive Chairman
PGPradip Ghate
Pradip GhateinChief Operating OfficerPradip Ghate brings nearly four decades of experience in vaccine and injectable manufacturing, with expertise spanning development, production, operations, and executive leadership across pharmaceutical and biological products. He has a track record of securing multimillion-dollar grants and proposals for vaccine and biotech initiatives.
DG
David GoeslinginChief Financial Officer
YLYves Leurquin
Yves LeurquininChief Executive OfficerHe brings more than 30 years of experience in general management, marketing, go-to-market strategy, sales, and government affairs across vaccine development and launch, with engagement across Europe, Latin America, the Middle East, Africa, and Asia.

Reported raises · per SEC filings

Form D private placements

$3.5M disclosed across 1 round · 2021

▶$3.5MraisedNov 2021 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Pradip GhateExecutive Officer
  • David GoeslingExecutive Officer
  • Subhash KapreExecutive Officer, Director
  • Yves LeurquinExecutive Officer
Offering amount
$95M
Amount sold
$3.5M
First sale
Nov 2021
Incorporated
Limited Liability Company, Washington
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Inventprise went on to found or lead other companies.

Emily Egerton-WarburtonVaccine R&D InternFounded Ligo BiosciencesAndrew FarnumMember Board of DirectorsFounded Variant Bio

Competitors · 2

by search overlap
IQVIA11 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Vaxcyte11 shared keywordsVaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques. Its pipeline includes pneumococcal conjugate vaccines (VAX-31 and VAX-24) and early-stage candidates targeting Group A Strep and Shigella.

Companies competing with Inventprise for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Inventprise - Strategic Investment Fundsif.gatesfoundation.org · Feb 2026New Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical Evaluation - BioSpacebiospace.com · Nov 2022Inventprise Receives $30M, Appoints New CEO and Expands Corporate Board - Inventpriseinventprise.com · Apr 2022Inventprise Announces Investment of up to $90 Million to Advance its 25 Valent Pneumococcal Conjugate Vaccine Candidate into Proof-of-Concept Clinical Trials - Inventpriseinventprise.com · Nov 2021Seattle-area startup Inventprise gets backing from Gates Foundation for pneumonia shot – GeekWiregeekwire.com · Nov 2021

Frequently asked questions

What does Inventprise do?
Inventprise is a clinical-stage vaccine developer using its proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker conjugation platform to create conjugate vaccines, including a lead pediatric pneumococcal conjugate vaccine (IVT PCV-25) and candidates for Group B Streptococcus and mRNA-based vaccines. The company also operates automated manufacturing facilities intended to supply global vaccine demand.
Who founded Inventprise?
Inventprise was founded by Subhash Kapre in 2012.
How much funding has Inventprise raised?
Inventprise has disclosed $3.5M raised across 1 round.
Where is Inventprise headquartered?
Inventprise is headquartered in Redmond, US.